-

Half-Year Liquidity Contract Statement for Valerio Therapeutics

PARIS--(BUSINESS WIRE)--Regulatory News:

Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO)

Under the liquidity contract entered into between Valerio Therapeutics and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2023:

- 368,174 shares
- € 144,918.05

- Number of executions on buy side on semester: 324
- Number of executions on sell side on semester: 244
- Traded volume on buy side on semester: 304,205 shares for € 69,976.87
- Traded volume on sell side on semester: 223,191 shares for € 56,117.81

As a reminder :

  • the following resources appeared on the last half year statement on 30 June 2023 on the liquidity account:

- 287,160 shares
- € 156,554.06

- Number of executions on buy side on semester: 509
- Number of executions on sell side on semester: 492
- Traded volume on buy side on semester: 634,648 shares for € 258,705.74
- Traded volume on sell side on semester: 923,185 shares for € 402,719.91

  • the following resources appeared on the liquidity account when the activity started:

- 87,612 shares
- € 196,423.24

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

Contacts

Valerio Therapeutics S.A.

Valerio Therapeutics

BOURSE:ALVIO
Release Versions
EnglishFrench

Contacts

Valerio Therapeutics S.A.

More News From Valerio Therapeutics

Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a pioneering biotechnology company in the field of next-generation precision therapies (“Valerio”, or the “Company”), provides an update on its operations and presents its financial results for the half-year ended 30 June 2026. “The first half of 2026 marked a decisive milestone in the consolidation of our strategic refocusing and in the transformation of Valerio Therapeutics. The operational launc...

Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors 

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the signing of a definitive share purchase agreement (the "SPA") and of the related contribution agreement (the "Contribution Agreement") for the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"), ba...

Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), provides an update on the contemplated acquisition of 100% of the share capital of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). On July 1, 2026, Valerio announced the submission of a binding offer for the Acquisition on the basis of an enterprise value of EUR 30 million....
Back to Newsroom